調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025

がん/腫瘍プロファイリングの世界市場予測：技術別（免疫アッセイ、NGS、PCR、in-situハイブリダイゼーション、マイクロアレイ）、がん種類別（乳房、肺、結腸直腸、前立腺、黒色腫）、バイオマーカー種類別（ゲノム、タンパク質）、用途別、地域別

◆タイトル：Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025
◆商品コード：MD 4803
◆調査・発行会社：MarketsandMarkets
◆発行日：2020年7月15日
◆ページ数：293
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥0見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarkets社はがん/腫瘍プロファイリングの世界市場が2020年83億ドルから2025年139ドルまで、年平均10.9％成長すると見込んでいます。本調査レポートでは、がん/腫瘍プロファイリングの世界市場を詳細に調査・分析し、イントロダクション、調査手法、プレミアムインサイト、市場概要、市場インサイト、技術別（免疫学的検査、次世代シーケンシング、高分子鎖反応、インサイチュハイブリダイゼーション、マイクロアレイ）分析、癌種類別（乳癌、肺癌、結腸直腸がん、前立腺がん、メラノーマ）分析、バイオマーカー種類別（遺伝的バイオマーカー、タンパク質バイオマーカー、その他）分析、用途別（研究、臨床）分析、地域別分析、競争状況、企業概要などを含めており、ご提供いたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・市場インサイト
・がん/腫瘍プロファイリングの世界市場規模：技術別（免疫学的検査、次世代シーケンシング、高分子鎖反応、インサイチュハイブリダイゼーション、マイクロアレイ）
・がん/腫瘍プロファイリングの世界市場規模：癌種類別（乳癌、肺癌、結腸直腸がん、前立腺がん、メラノーマ）
・がん/腫瘍プロファイリングの世界市場規模：バイオマーカー種類別（遺伝的バイオマーカー、タンパク質バイオマーカー、その他）
・がん/腫瘍プロファイリングの世界市場規模：用途別（研究、臨床）
・がん/腫瘍プロファイリングの世界市場規模：地域別
・競争状況
・企業概要

“The cancer/tumor profiling market is expected to grow at a CAGR of 10.9% in the forecast period.”
The global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9 %. Factors such as the increasing incidence of cancer, increasing demand for personalized medicine, increasing use of biomarkers in cancer profiling, increasing cancer research and funding, and technological advancements in the field are expected to drive the growth of the cancer/tumor profiling market. However, poor regulatory and reimburement scenario serves as a major challenge for the industry.

“By technology, the next generation sequencing segment holds the highest market share during the forecast period.”
Based on technology, the cancer/tumor profiling market is segmented into immunoassays, in situ hybridization, next generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and others. The immunoassays segment held the highest market share in 2019. The high market share of this segment can be attributed to the wide adoption of these assays as it is the gold standard to measure the presence and concentration of analytes in a sample.

“Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period.”
Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The lung cancer segment is projected to register the highest CAGR during the forecast period. The significant growth in the lung cancer is attributed to the high incidence rate of lung cancer and the increasing need for early diagnosis.

“By biomarker type, the genetic biomarker segment holds the highest market share during the forecast period.”
Based on biomarker type, the cancer/tumor profiling market is segmented genetic biomarkers, protein biomarkers, and other biomarkers. The genetic segment held the highest market share in 2019. The high market share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process.

“By application type, the research application segment holds the highest market share during the forecast period.”
Based on cancer type, the cancer/tumor profiling market is segmented research and clinical applications. The research application segment held the highest market share in 2019. The high market share of this segment can be attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the increased funding for cancer research is propelling the growth of the market.

“By Region, The Asia Pacific region holds the highest market share during the forecast period.”
The Asia Pacific holds the highest market share during the forecast period (2020 to 2025).
Rapidly incidence of cancer, growing proteomics and genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries, are supporting the growth of the cancer/tumor market in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45% and Tier 3–20%
• By Designation – C-level–35%, D-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the cancer/tumor profiling market
The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Holdings Inc. (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq (US), Histogene X (Belgium).

Research Coverage:
The report analyzes the cancer/tumor profiling market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region. The report also includes a product portfolio matrix of various cancer profiling products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by product and distribution channel.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
• Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.

【レポートの目次】

1 INTRODUCTION (Page No. – 36)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION & SCOPE
1.2.1 MARKETS COVERED
FIGURE 1 CANCER/TUMOR PROFILING MARKET
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 40)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.3 Key industry insights
2.2 MARKET SIZING & VALIDATION APPROACH
FIGURE 4 SEGMENTAL SHARE ANALYSIS ILLUSTRATION
FIGURE 5 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 49)
FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS (Page No. – 54)
4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 13 CHINA TO REGISTER THE FASTEST GROWTH IN THE CANCER/ TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2020-2025)
FIGURE 14 APAC TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD (2020-2025)
4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2020 VS. 2025)
FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2020 & 2025

5 MARKET OVERVIEW (Page No. – 58)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing incidence of cancer
FIGURE 17 GLOBAL CANCER INCIDENCE, 2008-2030
5.2.1.2 Increasing use of biomarkers in cancer profiling
5.2.1.3 Increasing cancer research and funding
5.2.1.4 Technological advancements
TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS
5.2.2 MARKET RESTRAINTS
5.2.2.1 High capital investment
5.2.2.2 Technical issues with sample collection and storage
TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicine
FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
5.2.3.2 Growing need for point-of-care diagnostics
TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 MARKET CHALLENGES
5.2.4.1 Low biomarker discovery-to-approval ratio
5.2.4.2 Poor regulatory and reimbursement scenario
TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS

6 INDUSTRY INSIGHTS (Page No. – 67)
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
6.2.1 INTEGRATION OF OMICS DATA
6.2.2 ADVANCES IN LIQUID BIOPSY
6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE
6.3 COVID-19 IMPACT ON THE CANCER/TUMOR PROFILING MARKET
FIGURE 20 IMPACT OF COVID-19 ON THE CANCER/TUMOR PROFILING MARKET

7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (Page No. – 71)
7.1 INTRODUCTION
7.2 COVID-19 IMPACT, BY TECHNOLOGY
FIGURE 21 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
7.3 IMMUNOASSAYS
7.3.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
TABLE 7 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 8 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.4 NEXT GENERATION SEQUENCING
7.4.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
TABLE 9 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 10 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.5 POLYMERASE CHAIN REACTION
7.5.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
TABLE 11 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 12 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.6 IN SITU HYBRIDIZATION
7.6.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
TABLE 13 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 14 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.7 MICROARRAYS
7.7.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
TABLE 15 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 16 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.8 MASS SPECTROMETRY
7.8.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS
TABLE 17 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
7.9 OTHER TECHNOLOGIES
TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 20 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (Page No. – 90)
8.1 INTRODUCTION
FIGURE 22 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
TABLE 21 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 22 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
8.2 BREAST CANCER
8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
TABLE 23 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 24 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
8.3 LUNG CANCER
8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
FIGURE 23 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
TABLE 25 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 26 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
8.4 COLORECTAL CANCER
8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
FIGURE 24 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
TABLE 27 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 28 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
8.5 PROSTATE CANCER
8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
TABLE 29 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
8.6 MELANOMA
8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 32 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
8.7 OTHER CANCERS
TABLE 33 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 34 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE (Page No. – 107)
9.1 INTRODUCTION
FIGURE 25 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
TABLE 35 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 36 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
9.2 GENETIC BIOMARKERS
9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
TABLE 37 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 38 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
9.3 PROTEIN BIOMARKERS
9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
TABLE 39 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 40 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
9.4 OTHER BIOMARKERS
TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 42 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION (Page No. – 116)
10.1 INTRODUCTION
10.2 COVID-19 IMPACT, BY APPLICATION
FIGURE 26 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
TABLE 43 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017-2019 (USD MILLION)
TABLE 44 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020-2025 (USD MILLION)
10.3 RESEARCH APPLICATIONS
TABLE 45 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 46 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
10.3.1 BIOMARKER DISCOVERY
10.3.1.1 Biomarkers are being exploited for the development of personalized or precision medicine
TABLE 47 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 48 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
10.3.2 PERSONALIZED MEDICINE
10.3.2.1 The field of personalized medicine is witnessing rapid growth in the area of oncology
TABLE 49 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 50 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
10.4 CLINICAL APPLICATIONS
TABLE 51 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 52 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
10.4.1 DIAGNOSTICS
10.4.1.1 Tumor profiling is rapidly gaining momentum in the area of diagnostics
TABLE 53 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 54 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
10.4.2 PROGNOSTICS
10.4.2.1 Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
TABLE 55 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 56 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
10.4.3 MONITORING & TREATMENT
10.4.3.1 Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
TABLE 57 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 58 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
10.4.4 SCREENING
10.4.4.1 Screening tests help in deciding if diagnostic tests are required by the patient
TABLE 59 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
TABLE 60 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

11 CANCER/TUMOR PROFILING MARKET, BY REGION (Page No. – 133)
11.1 INTRODUCTION
11.2 COVID-19 IMPACT, BY REGION
FIGURE 27 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT
TABLE 61 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017-2019 (USD MILLION)
TABLE 62 CANCER/TUMOR PROFILING MARKET, BY REGION, 2020-2025 (USD MILLION)
11.3 NORTH AMERICA
FIGURE 28 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
TABLE 64 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
TABLE 65 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 66 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 67 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 68 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 70 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 71 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 72 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 73 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 74 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.3.1 US
11.3.1.1 US dominates the North American cancer/tumor profiling market
TABLE 75 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 76 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 77 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 78 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 79 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 80 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 81 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 82 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 83 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 84 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.3.2 CANADA
11.3.2.1 Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
TABLE 85 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 86 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 87 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 88 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 89 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 90 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 91 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 92 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 93 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 94 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4 EUROPE
FIGURE 29 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
TABLE 96 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
TABLE 97 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 98 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,2020-2025 (USD MILLION)
TABLE 99 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 100 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 101 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 103 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 104 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 105 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 106 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.1 GERMANY
11.4.1.1 Advancements in proteomics and genomics research are expected to drive market growth
TABLE 107 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 108 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 109 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 110 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 111 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 112 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 113 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 114 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 115 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 116 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.2 UK
11.4.2.1 Growth in the life sciences industry and the increase in academia-industry partnerships will be the key factors driving the market
TABLE 117 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 118 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 119 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 120 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 121 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 122 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 123 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 124 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 125 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 126 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.3 FRANCE
11.4.3.1 Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
TABLE 127 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 128 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 129 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 130 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 131 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 132 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 133 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 134 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 135 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 136 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.4 ITALY
11.4.4.1 Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
TABLE 137 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 138 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 139 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 140 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 141 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 142 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 143 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 144 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 145 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 146 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.5 SPAIN
11.4.5.1 Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
TABLE 147 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 148 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 149 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 150 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 151 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 152 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 153 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 154 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 155 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 156 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.4.6 REST OF EUROPE
TABLE 157 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 158 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 159 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 160 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 161 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 162 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 163 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 164 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 165 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 166 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.5 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
TABLE 167 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,2017-2019 (USD MILLION)
TABLE 168 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
TABLE 169 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 170 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 171 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 172 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 173 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 174 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 175 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 176 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 177 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 178 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.5.1 JAPAN
11.5.1.1 Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
TABLE 179 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 180 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 181 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 182 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 183 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
TABLE 184 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
TABLE 185 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 186 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
TABLE 187 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
TABLE 188 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
11.5.2 CHINA
11.5.2.1 China has the fastest-growing research sector in the APAC region
TABLE 189 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
TABLE 190 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
TABLE 191 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
TABLE 192 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
TABLE 193 CHINA: CANCER/TUMOR PROFILING MARKET, BY B



★調査レポート[がん/腫瘍プロファイリングの世界市場予測：技術別（免疫アッセイ、NGS、PCR、in-situハイブリダイゼーション、マイクロアレイ）、がん種類別（乳房、肺、結腸直腸、前立腺、黒色腫）、バイオマーカー種類別（ゲノム、タンパク質）、用途別、地域別] ( Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025 / MD 4803) 販売に関する免責事項
[がん/腫瘍プロファイリングの世界市場予測：技術別（免疫アッセイ、NGS、PCR、in-situハイブリダイゼーション、マイクロアレイ）、がん種類別（乳房、肺、結腸直腸、前立腺、黒色腫）、バイオマーカー種類別（ゲノム、タンパク質）、用途別、地域別] ( Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025 / MD 4803) についてEメールでお問い合わせ

※関連データはありません。


◆H&Iグローバルリサーチ株式会社のお客様（例）◆